Anti-Mouse CD80 – Purified in vivo PLATINUM™ Functional Grade

Purified Recombinant Mouse CD80 (>98%)

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone 16-10A1 recognizes an epitope on mouse CD80.

CD80 is a highly glycosylated 60 kD protein that is part of the Ig superfamily and is significantly involved in immune cell activation in response to pathogens. CD80 is closely related to, and works in tandem with CD86 (B7-2) to prime T- cells. CD80 binds to CTLA-4 to deliver an inhibitory signal to T cells. The ligation of CD28 on T cells with CD80 and CD86 on APCs co-stimulates T cells resulting in enhanced cell activation, proliferation, and cytokine production. It is thought that CD80 interacts with a ligand on Natural Killer cells, activating the Natural Killer cell-mediated cell death of the CD80 carrier. The activation of Natural Killer cell-mediated death via CD80 interactions has potential as a possible cancer immunotherapy through the induction of CD80 expression on tumor cells.

CD80 is expressed on activated B cells, monocytes/macrophages, and dendritic cells.

CD28 (stimulatory), CD152(CTLA4) (inhibitory)

T cell costimulation